How is SCYNEXIS Inc (SCYX) stock performing in the market? Here is what you need to know

SCYNEXIS Inc is spearheading creative meds to possibly help a large number of patients overall needing new choices to survive and forestall hard-to-treat and drug-resistant diseases. SCYX is fostering their lead item applicant, ibrexafungerp, as an expansive range, intravenous (IV)/oral specialist for quite some time signs in both the local area and medical clinic settings. SCYX took a blow as the firm declared its public offering.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 21 April 2022, SCYX stock went somewhere around 19.11% in the recent exchanging meeting to reach $2.54. The stock announced its new low in the after-market against the earlier $3.11 which it came to in the standard meeting around the same time.

SCYX’s News

The organization started an endorsed public offering of its normal stock offers. In addition, the offering additionally incorporates pre-subsidized warrants for a normal stock for specific buyers, on Thursday.

The organization likewise plans to offer a 30-day choice for buying an extra 15% of offers in the first contribution. While every one of the offers in the contribution is to be sold by SCYX, their size and terms were not revealed. The conditions of the contribution would be uncovered in an outline supplement with the Securities Exchange Commission.

Besides, the book-running supervisor for the contribution is Guggenheim Securities to the organization.

Where does the industry stand?

The anti-fungal medications market endured a truly brutal shot from the pandemic that dramatically eased back development on the lookout. With all attention on creating medicines for the COVID-19 infection, even the current medicines for parasitic contaminations were shoved aside. Different variables that affected the market adversely were deficiencies of provisions, work terminations, and so on.

Then again, numerous Covid-19 cases were then analyzed to be experiencing a genuine fundamental contagious contamination that carried regard for the market. Presently, the counter parasitic medication market is supposed to enroll a growth rate of 3.5% somewhere in the range of 2022 and 2027 as it proceeds to recuperate from the flare-up of Covid-19 gradually.

Where does the SCYX stand?

While the market is still during the time spent recuperation as inventory network interruptions proceed, it was barely a year ago that SCYX emerged with its most memorable medication. The organization accomplished the milestone achievement of sending off its most memorable business item in 2021. Getting extra business protection model inclusion for the medication in Q1 of 2022 is as yet chipping away at building a wide antifungal establishment for it.

SCYX’s Valuation

The following table represents the few absolute metrics for the valuation of the firm.

Market Cap $96.96 M
Enterprise Value $36.10 M
Price/Sales 6.71
Price/Book 2.35
Enterprise Value/Revenue 2.74
Enterprise Value/EBITDA -1.10



The organization still can’t seem to demonstrate its worth after it sent off its most memorable business drug last year, thinking of it as falling beneath assumptions in past profit.